To assess the biological importance and therapeutic relevance of SET targeting via FTY720 in KMT2A-R-leukemia, we tested FTY720 in combination with daunorubicin in two KMT2A-R-patient-derived-xenograft (PDX) models in vitro. This evidence concerns the gene SET and leukemia.